Related Party Transactions	12 Months Ended
Jul. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 13 – RELATED PARTY TRANSACTIONS IDT Corporation The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT Corporation, or IDT, and payroll costs for the Company’s personnel that were paid by IDT. The Company also receives rental income from IDT and various companies under common control with IDT. The Company recorded expense of approximately $343 thousand and $322 thousand in related party services to IDT for the years ended July 31, 2022 and 2021, respectively, of which approximately $69 thousand and $136 thousand is included in Due to Related Parties at July 31, 2022 and 2021, respectively. IDT leases approximately 80,000 square feet of office space plus parking at 520 Broad Street, Newark, New Jersey and approximately 3,600 square feet of office space in Jerusalem, Israel. The Company invoiced IDT approximately $2.1 million, of which approximately $2.0 million is included in discontinued operations and $1.8 million, of which approximately $1.7 million is included in discontinued operations for office rent and parking during the years ended July 31, 2022 and 2021, respectively. As of July 31, 2022 and 2021, IDT owed the Company approximately $157 thousand and $168 thousand, respectively, for office rent and parking presented in trade accounts receivable within the consolidated balance sheet. During the year ended July 31, 2021, IDT exercised 43,649 warrants to purchase shares of Class B Common Stock. Cornerstone Pharmaceuticals The Company had provided Cornerstone Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas currently serves on the Board of Directors of Cornerstone Pharmaceuticals and owns an equity interest in Cornerstone Pharmaceuticals. The Company billed Cornerstone Pharmaceuticals $120 thousand and $480 thousand for the years ended July 31, 2022 and 2021, respectively. As of July 31, 2022 and 2021, Cornerstone Pharmaceuticals owed the Company $720 thousand, for which a full allowance for uncollectibility has been recorded, and $600 thousand, respectively, included in Due from Cornerstone Pharmaceuticals. Due to the Data Events, in the year ended July 31, 2022, the balance owed to the Company by Cornerstone Pharmaceuticals as of July 31, 2022, was fully reserved, resulting in a loss on related party receivable of $720 thousand (See Note 3). Pharma Holdings On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Cornerstone Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings. Related Party Rental Income The Company leases space to related parties (including IDT Corporation - see above) which represented approximately 58% and 65% for the years ended July 31, 2022 and 2021, respectively, which includes discontinued operations related party rental income pertaining to the 520 Property. The portion of related party rental income pertaining to the 520 Property has been classified in discontinued operations on the consolidated statements of operations and comprehensive loss for the years ended July 31, 2022 and 2021. See Note 18 for future minimum rent payments from related parties and other tenants. Investment in Altira In May 2020, the Company acquired a membership interest of 33.333% in Altira, a related party. In December 2020, the Company acquired an additional 33.333% membership interest in Altira, for an aggregate of a 66.666% membership interest (see Note 4). RP Finance For the years ended July 31, 2022 and 2021, respectively, the Company recognized a loss of $575 thousand and earnings of $383 thousand in income from its ownership interests of 37.5% in RP Finance, respectively. Howard Jonas, Chairman of the Board and Former Chief Executive Officer In December 2020, two entities, on whose Boards of Directors Howard Jonas, the Company’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. In connection with the purchases, each purchaser was granted warrants (the “Issued Warrants”) to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Issued Warrants have an exercise price of $22.91 per share and expired on June 6, 2022. The Issued Warrants were not exercised. The shares and Issued Warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. On June 22, 2022, the Company entered into a Stock Purchase Agreement (the “I9 SPA”) with I9 Plus, LLC. On July 6, 2022, pursuant to the I9 SPA, the Company sold 3,225,806 shares of the Company’s Class B common stock to I9 Plus, LLC at a price per share of $1.86 and an aggregate sale price of $6 million. LipoMedix Pharmaceuticals, Ltd. As of the date of the Share Purchase Agreement, on November 15, 2021, there was an outstanding loan balance including principal of $400 thousand and accrued interest of $21.8 thousand owed by LipoMedix to the Company on the note from March 2021. The amount due on the loan was netted against the $3.0 million aggregate purchase price due LipoMedix, resulting in a cash payment by the Company of approximately $2.6 million in exchange for the 15,975,000 shares purchased. As a result of the share purchase, the Company’s ownership of LipoMedix increased to approximately 84% with a noncontrolling interest of approximately 16%.

Related Party Transactions

12 Months Ended

Jul. 31, 2022

NOTE 13 – RELATED PARTY TRANSACTIONS

IDT Corporation

The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT Corporation, or IDT, and payroll costs for the Company’s personnel that were paid by IDT. The Company also receives rental income from IDT and various companies under common control with IDT. The Company recorded expense of approximately $343 thousand and $322 thousand in related party services to IDT for the years ended July 31, 2022 and 2021, respectively, of which approximately $69 thousand and $136 thousand is included in Due to Related Parties at July 31, 2022 and 2021, respectively.

IDT leases approximately 80,000 square feet of office space plus parking at 520 Broad Street, Newark, New Jersey and approximately 3,600 square feet of office space in Jerusalem, Israel. The Company invoiced IDT approximately $2.1 million, of which approximately $2.0 million is included in discontinued operations and $1.8 million, of which approximately $1.7 million is included in discontinued operations for office rent and parking during the years ended July 31, 2022 and 2021, respectively. As of July 31, 2022 and 2021, IDT owed the Company approximately $157 thousand and $168 thousand, respectively, for office rent and parking presented in trade accounts receivable within the consolidated balance sheet.

During the year ended July 31, 2021, IDT exercised 43,649 warrants to purchase shares of Class B Common Stock.

Cornerstone Pharmaceuticals

The Company had provided Cornerstone Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas currently serves on the Board of Directors of Cornerstone Pharmaceuticals and owns an equity interest in Cornerstone Pharmaceuticals. The Company billed Cornerstone Pharmaceuticals $120 thousand and $480 thousand for the years ended July 31, 2022 and 2021, respectively. As of July 31, 2022 and 2021, Cornerstone Pharmaceuticals owed the Company $720 thousand, for which a full allowance for uncollectibility has been recorded, and $600 thousand, respectively, included in Due from Cornerstone Pharmaceuticals.

Due to the Data Events, in the year ended July 31, 2022, the balance owed to the Company by Cornerstone Pharmaceuticals as of July 31, 2022, was fully reserved, resulting in a loss on related party receivable of $720 thousand (See Note 3).

Pharma Holdings

On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Cornerstone Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.

Related Party Rental Income

The Company leases space to related parties (including IDT Corporation - see above) which represented approximately 58% and 65% for the years ended July 31, 2022 and 2021, respectively, which includes discontinued operations related party rental income pertaining to the 520 Property. The portion of related party rental income pertaining to the 520 Property has been classified in discontinued operations on the consolidated statements of operations and comprehensive loss for the years ended July 31, 2022 and 2021. See Note 18 for future minimum rent payments from related parties and other tenants.

Investment in Altira

In May 2020, the Company acquired a membership interest of 33.333% in Altira, a related party. In December 2020, the Company acquired an additional 33.333% membership interest in Altira, for an aggregate of a 66.666% membership interest (see Note 4).

RP Finance

For the years ended July 31, 2022 and 2021, respectively, the Company recognized a loss of $575 thousand and earnings of $383 thousand in income from its ownership interests of 37.5% in RP Finance, respectively.

Howard Jonas, Chairman of the Board and Former Chief Executive Officer

In December 2020, two entities, on whose Boards of Directors Howard Jonas, the Company’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. In connection with the purchases, each purchaser was granted warrants (the “Issued Warrants”) to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Issued Warrants have an exercise price of $22.91 per share and expired on June 6, 2022. The Issued Warrants were not exercised. The shares and Issued Warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.

On June 22, 2022, the Company entered into a Stock Purchase Agreement (the “I9 SPA”) with I9 Plus, LLC. On July 6, 2022, pursuant to the I9 SPA, the Company sold 3,225,806 shares of the Company’s Class B common stock to I9 Plus, LLC at a price per share of $1.86 and an aggregate sale price of $6 million.

LipoMedix Pharmaceuticals, Ltd.

As of the date of the Share Purchase Agreement, on November 15, 2021, there was an outstanding loan balance including principal of $400 thousand and accrued interest of $21.8 thousand owed by LipoMedix to the Company on the note from March 2021. The amount due on the loan was netted against the $3.0 million aggregate purchase price due LipoMedix, resulting in a cash payment by the Company of approximately $2.6 million in exchange for the 15,975,000 shares purchased. As a result of the share purchase, the Company’s ownership of LipoMedix increased to approximately 84% with a noncontrolling interest of approximately 16%.